Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2003 December;15(4) > Minerva Biotecnologica 2003 December;15(4):235-44

CURRENT ISSUEMINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

 

ORIGINAL ARTICLES  MICROARRAY MEETING 2003: III CONVEGNO ITALIANO SULLA TECNOLOGIA
Segrate (MI), 9-10 Giugno 2003


Minerva Biotecnologica 2003 December;15(4):235-44

language: English

Application of a cDNA micro­ar­ray for the anal­y­sis of mus­cu­lar dys­tro­phies and child­hood leu­ke­mi­as

Campanaro S. 1, De Pittà C. 1, Celegato B. 1, Millino C. 1, Romualdi C. 1, Pacchioni B. 1, Trevisan S. 1, Bellin M. 1, Cagnin S. 1, Tombolan L. 1, Fanin M. 2, Pegoraro E. 2, TE Kronnie G. 3, Pescatori M. 4, Valle G. 1, Basso G. 3, Ricci E. 4, Angelini C. 2, Lanfranchi G. 1

1 CRI­BI Biotechnology Center and Departement of Biology, University of Padua, Padua, Italy;
2 Department of Neurosciences, University of Padua, Padua, Italy;
3 Department of Pediatrics, University of Padua, Padua, Italy;
4 Institute of Neurology, Catholic University, Rome, Italy and ­UILDM-Centre for Neuromuscular Diseases, Rome, Italy


FULL TEXT  REPRINTS


Aim. Microarray tech­nique can meas­ure the expres­sion of thou­sands of ­genes simul­ta­ne­ous­ly and can iden­ti­fy sub­tle chang­es in expres­sion ­between dif­fer­ent bio­log­i­cal ­states.
Methods. Using our cDNA col­lec­tion ­obtained ­from system­at­ic sequenc­ing of cDNA librar­ies ­from skel­e­tal mus­cle, ­heart and ­bone mar­row tis­sues, we ­have devel­oped a micro­ar­ray com­posed of 4 670 sequenc­es cor­re­spond­ing to the 400-500 bp ­region locat­ed at the 3’-end of cDNA tran­scripts.
Results. We ­used ­this micro­ar­ray plat­form in ­order to inves­ti­gate the expres­sion pro­file in 4 dif­fer­ent pathol­o­gies: ­limb gir­dle mus­cu­lar dys­tro­phy ­type 2B (­LGMD 2B), facios­ca­pu­lo­hu­me­ral­ mus­cu­lar dys­tro­phy (­FSHD1A), con­gen­i­tal mus­cu­lar dys­tro­phy (CMD) and a ­group of child­hood leu­kae­mi­as. Our aim is to com­pare dif­fer­ent pathol­o­gies in ­order to iden­ti­fy sig­nif­i­cant ­genes ­whose expres­sion char­ac­ter­ize ­each sin­gle dis­ease.
Conclusion. The cDNA micro­ar­ray plat­form devel­oped in our labor­a­to­ry ­allow the iden­tifi­ca­tion of dif­fe­ren­tial­ly ­expressed ­genes in mus­cu­lar dys­tro­phies and in child­hood leu­kae­mi­as in ­order to bet­ter ­define the mole­cular mech­a­nism of ­these pathol­o­gies. Moreover our micro­ar­ray experi­ments iden­ti­fy dif­fer­ent ­forms of the ­same pathol­o­gy on the ­base of the tran­scrip­tion­al pro­file.

top of page